USCOM Ltd
UCM
Company Profile
Business description
USCOM Ltd is engaged in the development, design, manufacture, and marketing of premium non-invasive cardiovascular and pulmonary medical devices. The company's geographical segment includes Australia, Asia, America, Europe, and Other regions. The company generates maximum revenue from Australia. The company offers USCOM 1A, a non-invasive hemodynamic monitor that measures cardiovascular function; BP+, a supra-systolic oscillometric central blood pressure monitor that measures blood pressure and blood pressure waveforms at the heart, SPIROSONIC, a pulmonary function testing device based on multi-path ultrasound technology.
Contact
66 Clarence Street
Suite 2, Level 8
SydneyNSW2000
AUST: +61 292474144
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
30 June 2026
Employees
11
Stocks News & Analysis
stocks
Beaten down real estate share receives legal blow
Real estate share remains cheap despite losing airport legal battle.
stocks
OpenAI joins the mega-AI lab IPO race, but timing is uncertain
The ChatGPT maker joined Anthropic in filing a confidential S-1 with the SEC, teeing up a future IPO.
stocks
What happens if Tesla and SpaceX merge?
We see a solid business case for a merger, but not without hurdles, including Tesla shareholders’ concern about SpaceX’s valuation.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,006.10 | 29.10 | 0.32% |
| CAC 40 | 8,350.87 | 150.08 | 1.83% |
| DAX 40 | 24,635.30 | 425.59 | 1.76% |
| Dow JONES (US) | 51,202.26 | 353.51 | 0.70% |
| FTSE 100 | 10,471.72 | 167.84 | 1.63% |
| HKSE | 24,718.10 | 468.81 | 1.93% |
| NASDAQ | 25,888.84 | 79.18 | 0.31% |
| Nikkei 225 | 66,020.04 | 1,802.77 | 2.81% |
| NZX 50 Index | 13,393.87 | 191.71 | 1.45% |
| S&P 500 | 7,431.46 | 37.16 | 0.50% |
| S&P/ASX 200 | 8,804.00 | 30.50 | 0.35% |
| SSE Composite Index | 4,031.51 | 44.50 | 1.12% |